BPMC Blueprint Medicines Corp

Price (delayed)

$100.99

Market cap

$5.63B

P/E Ratio

17.5

Dividend/share

N/A

EPS

$5.77

Enterprise value

$5.15B

Sector: Healthcare
Industry: Biotechnology

Highlights

The net income has soared by 192% YoY and by 184% QoQ
Blueprint Medicines's EPS has surged by 175% QoQ and by 174% YoY

Key stats

What are the main financial stats of BPMC
Market
Shares outstanding
55.73M
Market cap
$5.63B
Enterprise value
$5.15B
Valuations
Price to earnings (P/E)
17.5
Price to book (P/B)
4.23
Price to sales (P/S)
6.87
EV/EBIT
16.25
EV/EBITDA
15.65
EV/Sales
6.35
Earnings
Revenue
$811.16M
EBIT
$316.94M
EBITDA
$329.03M
Free cash flow
$360.58M
Per share
EPS
$5.77
Free cash flow per share
$6.54
Book value per share
$23.88
Revenue per share
$14.7
TBVPS
$28.24
Balance sheet
Total assets
$1.56B
Total liabilities
$238.18M
Debt
$91.41M
Equity
$1.32B
Working capital
$731.55M
Liquidity
Debt to equity
0.07
Current ratio
7.64
Quick ratio
7.48
Net debt/EBITDA
-1.46
Margins
EBITDA margin
40.6%
Gross margin
100%
Net margin
41.1%
Operating margin
40.1%
Efficiency
Return on assets
33.3%
Return on equity
43.7%
Return on invested capital
49%
Return on capital employed
21.9%
Return on sales
39.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BPMC stock price

How has the Blueprint Medicines stock price performed over time
Intraday
-1.48%
1 week
-6.73%
1 month
-14.68%
1 year
25.83%
YTD
-9.95%
QTD
-9.95%

Financial performance

How have Blueprint Medicines's revenue and profit performed over time
Revenue
$811.16M
Gross profit
$810.86M
Operating income
$325.29M
Net income
$333.22M
Gross margin
100%
Net margin
41.1%
The net income has soared by 192% YoY and by 184% QoQ
The operating income has soared by 187% YoY and by 180% from the previous quarter
BPMC's net margin has soared by 108% since the previous quarter and by 102% year-on-year
The operating margin has soared by 107% from the previous quarter and by 102% YoY

Growth

What is Blueprint Medicines's growth rate over time

Valuation

What is Blueprint Medicines stock price valuation
P/E
17.5
P/B
4.23
P/S
6.87
EV/EBIT
16.25
EV/EBITDA
15.65
EV/Sales
6.35
Blueprint Medicines's EPS has surged by 175% QoQ and by 174% YoY
Blueprint Medicines's equity has surged by 156% YoY and by 127% QoQ
The price to book (P/B) is 33% lower than the 5-year quarterly average of 6.3 and 31% lower than the last 4 quarters average of 6.1
The P/S is 93% below the 5-year quarterly average of 102.2 and 83% below the last 4 quarters average of 40.7

Efficiency

How efficient is Blueprint Medicines business performance
The ROIC has soared by 175% YoY and by 167% from the previous quarter
The company's return on assets has surged by 167% QoQ and by 161% YoY
BPMC's return on equity has surged by 162% since the previous quarter and by 157% year-on-year
Blueprint Medicines's return on sales has surged by 107% QoQ and by 102% YoY

Dividends

What is BPMC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BPMC.

Financial health

How did Blueprint Medicines financials performed over time
BPMC's total assets has surged by 111% year-on-year and by 91% since the previous quarter
BPMC's quick ratio is up by 42% since the previous quarter and by 40% year-on-year
BPMC's debt is 93% smaller than its equity
Blueprint Medicines's equity has surged by 156% YoY and by 127% QoQ
BPMC's debt to equity has dropped by 63% year-on-year and by 56% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.